Evidence map›Paper›PMID 25906771›Full record

ArticleBMC immunology2015

Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis.

Patricia J McLaughlin, Daniel P McHugh, Marcus J Magister, Ian S Zagon

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Immunology and Immunotherapy of Endometriosis.Journal of clinical medicine · 2021
    Review
  6. Article
  7. Review
  8. Article
  9. Chronic Methadone Use Alters the CD8Journal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  10. Article
  11. Intermittent blockade of OGFr and treatment of autoimmune disorders.Experimental biology and medicine (Maywood, N.J.) · 2018
    Review
  12. Article
  13. Article
  14. Article
  15. Featured Article: Serum [MetExperimental biology and medicine (Maywood, N.J.) · 2017
    Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Patricia J McLaughlinDepartment of Neural & Behavioral Sciences, Pennsylvania State University College of Medicine, 500 University Drive, MC H109, Hershey, PA, USA. pxm9@psu.edu.
Daniel P McHughDepartment of Neural & Behavioral Sciences, Pennsylvania State University College of Medicine, 500 University Drive, MC H109, Hershey, PA, USA. danielmch@pcom.edu.
Marcus J MagisterDepartment of Neural & Behavioral Sciences, Pennsylvania State University College of Medicine, 500 University Drive, MC H109, Hershey, PA, USA. mmagister@hmc.psu.edu.
Ian S ZagonDepartment of Neural & Behavioral Sciences, Pennsylvania State University College of Medicine, 500 University Drive, MC H109, Hershey, PA, USA. isz1@psu.edu.
Pennsylvania State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExperimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis, is induced by immunization of mice with myelin oligodendrocytic glycoprotein (MOG35-55) injections, and after 9 days, mice develop behavioral signs of chronic progressive EAE. Proliferation of T and B cells located in peripheral lymph tissues such as spleen and inguinal lymph nodes of C57BL/6J mice are stimulated. The opioid growth factor-opioid growth factor receptor (OGF-OGFr) axis has been shown to effectively limit progression of chronic EAE when mice are treated at the time of induction or at time of established disease. In addition to repressed behavioral profiles, spinal cord neuropathology is diminished in mice treated with OGF or low dosages of naltrexone (LDN). However, there is little or no information on peripheral lymphocyte dynamics following immunization of mice with MOG antigen and treatment with OGF or LDN.

methodsSix-week old female mice were immunized with MOG35-55 and were injected intraperitoneally with OGF or a low dosage of naltrexone (LDN) beginning at the time of immunization; saline-injected immunized mice served as controls. Normal mice received saline for all injections. Periodically over a 2 week period, spleens and inguinal lymph nodes were removed, total lymphocytes counted, and subpopulations of CD4+ and CD8+ specific T-cells, as well as B lymphocytes, were determined by flow cytometry. On day 15 of treatment, lumbar spinal cord tissue was removed; CNS lymphocytes isolated, and assayed for Th1, Th2, and Th17 markers by flow cytometry.

resultsExogenous OGF or endogenous OGF following LDN suppressed T and B lymphocyte proliferation in the spleen and inguinal lymph nodes of MOG-immunized mice. Suppression of peripheral immune cell CD4+ and CD8+ T cell proliferation at 5 and 12 days correlated with reductions in clinical behavior. EAE mice treated with OGF for 15 days displayed elevated Th1 and Th17 cells; no subpopulations of Th2-specific T cells were noted.

conclusionsOGF or LDN repress proliferation of CD4+ and CD8+T cells and B220+ B lymphocytes in the spleen and lymph nodes of immunized mice within a week of immunization. These data provide novel mechanistic pathways underlying the efficacy of OGF and LDN therapy for MS.

Indexed as

ImmunizationAnalgesics, OpioidAnimalsBehavior, AnimalB-LymphocytesCell ProliferationEncephalomyelitis, Autoimmune, ExperimentalFemaleIntracellular SpaceLymph NodesLymphocyte CountLymphocyte SubsetsMice, Inbred C57BLMyelin-Oligodendrocyte GlycoproteinNaltrexoneSpleenAnalgesics, OpioidMyelin-Oligodendrocyte GlycoproteinNaltrexone

Identifiers

PMID25906771
PMCPMC4407783
OpenAlexW2084761932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.